English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background: Outcomes of patients newly diagnosed with atrial fibrillation (AF) in the post-vitamin K antagonist only era are not well known. Aim: To determine the two-year outcomes of patients newly diagnosed with AF, and the effectiveness of oral anticoagulants in everyday practice. Design &amp; Setting: Observational prospective cohort study in UK primary care. Method: 3574 patients aged ≥18 years with a new AF diagnosis were enrolled.  We applied a propensity score using an overlap weighting scheme to obtain unbiased estimates of the treatment effect of anticoagulation vs no anticoagulation on the occurrence of death, non-haemorrhagic stroke/systemic embolism(SE) and major bleeding within 2 years of diagnosis. Results: Overall, 65.8% received anticoagulant therapy, 20.8% received an antiplatelet only; 13.4% received neither.    During the study period, the overall incidence rates (95% CI) of all-cause mortality, non-haemorrhagic stroke/SE, and major bleeding were 4.15 (3.69 to 4.66), 1.45 (1.19 to 1.77), and 1.21 (0.97 to 1.50) per 100 person-years respectively.  Anticoagulation treatment compared with no anticoagulation treatment was associated with significantly lower all-cause mortality aHR 0.70 (95% CI 0.53 to 0.93), significantly lower risk of non-haemorrhagic stroke/SE (aHR 0.39 [95% CI 0.24 to 0.62]) and a non-significant higher risk of major bleeding (aHR 1.31 [(95% CI 0.77 to 2.24]). Conclusions: Our data support a benefit of anticoagulation in reducing stroke and death, without an increased risk of a major bleed among patients with new onset AF.   Anticoagulation of the group of patients at high risk of stroke not receiving anticoagulation may further improve outcomes.

Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF